PhRMA prevails in 340B orphan drug tussle
This article was originally published in Scrip
Executive Summary
A US district court judge has concluded the Department of Health and Human Services (HHS) lacked statutory authority when it issued a final rule last year that permitted certain healthcare facilities to purchase orphan drugs intended to be used for non-orphan indications at discounted prices under a federal program.